Joel Pekow

Appearances

RISANKIZUMAB EFFECTIVENESS IN USTEKINUMAB-NAIVE AND USTEKINUMAB EXPERIENCED PATIENTS WITH CHROHN'S DISEASE: REAL WORLD DATA FROM A LARGE TERTIARY CENTER
Date
May 21, 2024
<div style="direction: ltr;">BACKGROUND AND AIMS: Risankizumab and ustekinumab are both IL23 inhibitors approved the treatment of moderate to severe Crohn’s disease (CD)…
Presenter
Adar Zinger
Speakers
David Choi
Natalie Choi
Evan Fear
Zachary Fine
Russell Cohen
Sushila Dalal
Noa Krugliak Cleveland
Joel Pekow
David Rubin